Product Program year 2025 Source: CMS Open Payments

Lyfgenia

Drug Gene Therapy

NDC 73554-1111-1

Open in the dashboard

General payments

$108,329

309 payments

Research payments

$0

0 payments

Through program year 2025, $108,329 in general payments and $0 in research payments were reported against Lyfgenia (Gene Therapy).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $108,329 309

Breakdown

Who paid General payments · program year 2025
  1. bluebird bio, Inc. $108,329 309 payments
Top recipients General payments · program year 2025
  1. Stacey Rifkin-Zenenberg Hospice and Palliative Medicine · Hackensack, NJ $6,573 6% · 9 payments
  2. Sonali Chaudhury Pediatric Hematology-Oncology · Chicago, IL $5,763 5% · 10 payments
  3. Monica Bhatia Pediatric Hematology-Oncology · New York, NY $5,599 5% · 9 payments
  4. Tami John Pediatric Hematology-Oncology · Palo Alto, CA $5,438 5% · 9 payments
  5. Uroosa Ibrahim Medical Oncology · New York, NY $5,380 5% · 10 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pediatric Hematology-Oncology Pediatrics $60,204 60% · 70 practitioners
  2. Hematology & Oncology Internal Medicine $13,066 13% · 20 practitioners
  3. Hematology Internal Medicine $7,538 8% · 10 practitioners
  4. Hospice and Palliative Medicine Pediatrics $6,573 7% · 1 practitioner
  5. Medical Oncology Internal Medicine $6,038 6% · 6 practitioners

The top 5 of 18 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $16,453 15% · 16 recipients
  2. New York $14,794 14% · 8 recipients
  3. Florida $14,018 13% · 17 recipients
  4. Massachusetts $10,803 10% · 10 recipients
  5. New Jersey $7,140 7% · 6 recipients

The top 5 of 28 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

309 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record